



Cite this: *Food Funct.*, 2022, **13**, 1299

Healthy and pro-inflammatory gut ecology plays a crucial role in the digestion and tolerance of a novel Gluten Friendly™ bread in celiac subjects: a randomized, double blind, placebo control *in vivo* study†

Angelo Andriulli,^{‡a} Antonio Bevilacqua,^{‡b} Orazio Palmieri,^{‡a} Anna Latiano,^a Rosanna Fontana,^a Domenica Gioffreda,^a Stefano Castellana,^c Tommaso Mazza,^{id c} Anna Panza,^a Claudia Menzaghi,^d Elvira Grandone,^e Lazzaro di Mauro,^f Ivana Decina,^g Michele Tricarico,^g Daniela Musaico,^b Markku Mäki,^h Jorma Isola,ⁱ Alina Popp,^j Juha Taavela,^k Leonardo Petruzzi,^b Milena Sinigaglia,^b Maria Rosaria Corbo^{*b} and Carmela Lamacchia^{id *b,g}

Gluten Friendly™ (GF) is a new gluten achieved through a physicochemical process applied to wheat kernels. The goal of this research was to assess the *in vivo* effects of Gluten Friendly™ bread on celiac gut mucosa and microbiota. In a double-blind placebo-controlled intervention study, 48 celiac disease (CD) patients were randomized into 3 groups to eat 100 g of bread daily, containing different doses (0; 3 g; 6 g) of GF for 12 weeks. The small-bowel morphology (VH/CrD), intraepithelial densities of CD3+, celiac serology, MUC2, CB1, gut permeability, proinflammatory cytokines, gluten in stools, symptoms, and gut microbial composition were assessed. All 48 CD subjects experienced no symptoms. K-means analysis evidenced celiac subjects clustering around unknown parameters independent of GF dosage: K1 35%; K2 30%; K3 35%. VH/CrD significantly decreased in K1 and K2. VH/CrD did not correlate with IEL increase in K2. 33-mer was not detected in 47% and 73% of patients in both K1 and K2, respectively. VH/CrD and IEL did not change significantly and strongly correlated with the absence of 33-mer in K3. Inflammation and VH/CrD decrease are strongly related with the presence of proinflammatory species at the baseline. A boost in probiotic, butyrate-producing genera, is strongly related with GF tolerance at the end of the trial. Our research suggests that a healthy and proinflammatory ecology could play a crucial role in the digestion and tolerance of the new gluten molecule in celiac subjects. However, GF can be completely digested by gut microbiota of CD subjects and shapes it toward gut homeostasis by boosting healthy butyrate-producing populations. The clinical trial registry number is NCT03137862 (<https://clinicaltrials.gov>).

Received 16th February 2021

Accepted 18th October 2021

DOI: 10.1039/d1fo00490e

rsc.li/food-function

^aDivision of Gastroenterology, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

^bUniversità degli Studi di Foggia, Dipartimento di Scienze dell'Agricoltura, degli Alimenti e dell'Ambiente, Foggia, Italy. E-mail: carmela.lamacchia@unifg.it, mariarosaria.corbo@unifg.it

^cBioinformatics Unit, Fondazione IRCCS-Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo (Foggia), Italy

^dResearch Unit of Diabetes and Endocrine Diseases, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

^eAtherosclerosis and Thrombosis Unit, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

^fImmunohaematology and Transfusion Medicine Service, Fondazione IRCCS-Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy

^gNew Gluten World s.r.l., Foggia, Italy

^hFaculty of Medicine and Health Technology, Tampere University and Tampere University Hospital Tampere, Finland

ⁱFaculty of Medicine and Health Technology, Tampere University and Jilab Inc., Tampere, Finland

^jUniversity of Medicine and Pharmacy "Carol Davila" and National Institute for Mother and Child Health "Alessandrescu-Rusescu", Bucharest, Romania

^kDepartment of Internal Medicine, Central Finland Central Hospital, Jyväskylä, Finland

†Electronic supplementary information (ESI) available. See DOI: 10.1039/d1fo00490e

‡A. Andriulli, A. Bevilacqua and O. Palmieri equally contributed to this work, while C. Lamacchia and M.R. Corbo are co-corresponding authors.



Introduction

Celiac disease (CD) is a chronic multiorgan autoimmune disorder that is triggered by dietary gluten proteins in genetically predisposed individuals. Environmental factors such as gut microbiota variations may be implicated in the pathogenesis of CD.¹ In fact, gastrointestinal dysbiosis is linked with the inflammatory milieu in celiac patients.²

In CD patients, the mucosal layer fails to stabilize the gut microbiota, exposing the host to harmful antigens and pathogens.² Such dysbiosis is characterized by a reduction of intra- and inter-genera biodiversity,³ showing an imbalance between beneficial bacteria and potentially pathogenic or proinflammatory species, as compared to healthy subjects.⁴

Gluten Friendly™ (GF) is a new type of gluten⁵ achieved through a patented, physicochemical process that is applied to wheat kernels before milling. GF has shown, *in vitro*, some unprecedented and very positive characteristics such as (i) reduced immunoreactivity on gut-derived T-cell lines from celiac patients,⁶ (ii) reduced the immunogenicity in treated flours by R5 Elisa test and cross-reactivity toward antibodies recognizing the antigenic epitope of gluten proteins in treated wheat kernels,^{5,7} (iii) positive modulation of celiac gut microbiota with an increase in *Lactobacillus* spp. and *Bifidobacterium* spp.^{8,9} and (iv) increased Transepithelial Electrical Resistance (TEER) in human intestinal goblet cells.¹⁰

GF safety and efficacy was tested *in vitro* on T lines generated by the intestinal mucosa of celiac patients. The cells of each line, highly reactive to gluten, were analyzed for their reactivity to ethanolic extracts obtained from various flours pre- and post-“Gluten Friendly™” treatment. The ethanolic extracts were digested with pepsin and trypsin and subjected to deamidation with tTG. No immunological reactivity, measured as the production of interferon-gamma, to gluten extracted from flour treated according to the GF method to the concentrations of 50 and 100 µg mL⁻¹, was observed.⁶

GF cytotoxicity assays performed both on mononuclear cells from peripheral blood (PBMCs) from 2 healthy donors and on HT29-Human Colon Epithelial Cells¹⁰ showed always high cell viability and no variations in gamma interferon production in the presence of various preparations.

In a double-blind placebo-controlled clinical study, we challenged celiac patients with GF for 12 weeks. The goal of this research was to assess the *in vivo* effects of Gluten Friendly™ bread on celiac gut mucosa and microbiota. Histological, serological, and metagenomic data were recorded. Symptom charts were collected before, during, and after trial. GF clinical results were compared to previous gluten challenge literature. Finally, we carried out the statistical analysis of celiac gut microbiota composition and variations.

Our research explored the following open questions: (a) What are the effects of GF bread on the serology and histology of celiac patients? (b) Could these effects be mediated by the microbiota? (c) Could there be markers and/or predictors of the GF effect? (d) How does the microbiota ecology at the baseline affect the response of celiac patients to GF? (e) Can GF

modulate the microbiota in celiac subjects as suggested by the *in vitro* studies?

Subjects and methods

Therapeutic intervention study

A prospective, double-blind, placebo-controlled, randomized trial on young and adult subjects with biopsy-proven Celiac Disease (CD) was carried out at the Division of Gastroenterology, Fondazione IRCCS Casa Sollievo della Sofferenza (CSS) Hospital, in San Giovanni Rotondo, Italy. The study protocol was approved by the Ethics Committee of the hospital, and was in compliance with the Good Clinical Practice guidelines of the Helsinki Declaration.

Ethical approval was granted by the local Ethics Committee (46/CE). The study was registered on Clinicaltrials.gov (Identifier: NCT03137862).

Study subjects. Patients were recruited between April and September 2017 on the basis of retrospective analyses of the database of the clinical information at CSS Hospital. At the time of inclusion, subjects had a biopsy-supported diagnosis of CD, were positive for HLA-DQ2 or HLA-DQ8 genotypes, and were in remission on a Gluten Free Diet (GFD) for a minimum of 2 years. Remission was defined as (1) negative serology for CD, namely, anti-tissue transglutaminase IgA antibodies, initially screened through a rapid Biocard Celiac test (Anibiotech, Vantaa, Finland) and confirmed by a serum enzyme-linked immunosorbent assay (ELISA) test (Quanta Lite tTG IgA, Inova Diagnostics, Inc., San Diego, CA; (2) negative serology for anti-endomysial antibodies (EMA) at the pre-screening visit (Monkey Endomysium, Bio-Rad, Milan, Italy); (3) on a GFD for at least 24 months; and (4) the absence of symptoms that prompted initial diagnosis. After obtaining written informed consent, the subjects underwent a medical history interview, physical examination, laboratory tests, and Upper Gastrointestinal Endoscopy (UGE). At screening, all the subjects were tested for human leucocyte antigen genotype DQ2 and DQ8, using a commercially available Sequence-Specific Oligonucleotide hybridization kit (LABType XR, One Lambda, Canoga Park, CA).

At the screening period and week 12, participants were asked to consume a multi-sugar drink for a gut permeability test: 5 g lactulose (Duphalac, Solvay Pharmaceuticals Ltd), 1 g Dmannitol ≥98% (Sigma-Aldrich, UK), and 20 g of Sucrose (Sigma-Aldrich, UK) in 200 mL of water.¹¹ The study subjects were then instructed to collect spot urine samples for 5 hours. The subjects also provided a fecal sample for microbiome analysis and gluten quantification in stools.

All the subjects were followed closely and instructed to maintain their usual GFD. From week 0 to week 12, they were called weekly *via* telephone to verify the study on bread consumption, adherence to GFD, and compliance to the study protocol. Any protocol violation (including ingestion of prescription drugs) was registered. The subjects were also asked



Patients and public involvement. Patients were involved in the study, in particular, in the design and dissemination plans of our research.

Study treatment

Raw materials and “Gluten Friendly™” flour. Wheat kernels (mixtures of soft Italian grains containing 6% of gluten) used in this study to prepare GF flour were supplied by Casillo group S.p.A. (Corato, Italy). The grains were harvested and threshed, then treated with microwave energy according to the patented “Gluten Friendly™” technology.⁶ The technology has since been further improved.¹² Specifically, 100 g of cleaned wheat grains were dampened to achieve 15–18% moisture; moisture was evaluated using a Halogen Moisture Analyzer (Mettler Toledo HB43-S, Switzerland). The kernels were then heated with microwave (DeLonghi, Italy, for about 1 min between 1000 and 750 W), followed by a phase of slow evaporation of the water content. Rapid heating and slow evaporation were repeated until a temperature of 80–90 °C was reached, as measured with a thermal camera (FLUKE i 20, Italy), and a moisture level of 13–13.5%. After microwave treatment, GF wheat kernels were cooled and dried at room temperature (24 °C) for 12–24 h, and then ground with an automatic laboratory mill MCKA (Bühler AG, Azwil, Switzerland, diameter of grid 118–180 µm) to achieve GF flour.

GF bread preparation. GF bread buns for the study were baked in the laboratories of Casillo Group S.p.a. (Corato, Ba). After some preliminary experiments, the recipe was optimized in order to have two actual amounts of GF in the bread: 3 g (group B) or 6 g (group C).

The recipe was as follows.

1. Group B: 50 g of GF flour, 50 g of corn/rice starch, 2.5% yeast, 2% salt, 65% water. The actual content of GF was 3 g per day (1.5 g in each bun; see the protocol reported in the following lines).
2. Group C: 100 g of GF flour, 2.5% yeast, 2% salt, 65% water; the actual content of GF was 6 g per day (3.0 g in each bun; see the protocol reported in the following lines).
3. The control bread (group A) was prepared with the following ingredients: 100 g of corn/rice starch, 2.5% yeast, 2% salt, 65% water. The actual content of GF was 0 g (gluten free bread).

Doughs were prepared by mixing all the ingredients in a dough mixer, then leavening for approximately 20 min (at 28/30 °C and 70% humidity) and finally shaped into buns of 50 g each. The leavened bread buns were placed on Teflon perforated trays and baked in an oven at 220 °C for 20 min. The bread buns (2 buns of 50 g per day) were baked daily, packed in a controlled atmosphere (N₂/CO₂, 30/70%), and home delivered once a week to all the study participants.

Analyses

Endoscopy. UGE was undertaken by experienced endoscopists from the Endoscopic Unit of the Division of Gastroenterology at CSS Hospital. UGE video recordings were cross-checked by an independent observer to ensure consist-

ency in the assessment of the macroscopic appearance of the descending duodenum and the biopsy samplings. UGE was performed with an Olympus GIF240 (Olympus, Tokyo, Japan), and duodenal biopsies were performed distally to the Vater's papilla using an Olympus FB-240K biopsy forceps (2.8 mm standard oval with needle). All procedures were performed by means of pharyngeal local anesthesia and conscious sedation. Deep sedation under strictly controlled anesthesia was used in selected cases. The presence of macroscopic features suggestive of CD (mosaic pattern, scalloping, loss of folds, nodularity, and visible submucosal vascular pattern) was recorded in all the cases.

Biopsies and histology. In total, 6 biopsy specimens from the distal second part of the duodenum using a one-bite per-pass technique were taken during each UGE. Four specimens were immediately immersed in formalin and shipped to Jilab Inc. in Tampere, Finland, where they were centrally processed to ensure uniform specimen and orientation. Two biopsy specimens were used for tissue EMA evaluation (Antiendomysium biopsy, Eurospital, Trieste, Italy).

Histology. Routinely formalin-fixed samples were processed for paraffin blocks using a standard paraffin-infiltration protocol. Each biopsy was embedded in a separate paraffin block under a dissection microscope, aiming at a perpendicular cutting plane to the mucosal lumen surface.¹³ A crucial step in the procedure involves training laboratory technicians to obtain correctly oriented cuttings of biopsy specimens for morphometric evaluation. Six tissue sections (thickness 3–4 µm) were cut on the SuperFrost Plus microscope objective slides from each block by tilting the block 5–10 degrees between each cut. For VH/CrD measurements, the slides were stained with hematoxylin and eosin.

Immunohistochemistry. Immunohistochemistry of IELs was done with anti-CD3 antibody (Clone SP7, REF: RM-9107-S1, Thermo Fisher Scientific, Waltham, MA. Diluted 1 : 300). Crypt cell proliferation index was determined with anti-Cyclin B1 Ab-4 antibody (Clone GNS11, REF: MS-869-P1, NeoMarkers Inc., Fremont, CA. Diluted 1 : 100). The expression of MUC2 in the villus epithelium goblet cells was visualized with anti-MUC2 antibody (Clone BSB-45, REF: BSB 6160, Bio SB Inc., Santa Barbara, CA. Diluted 1 : 250). A standard IHC protocol using high-pH antigen retrieval (Tris-EDTA buffer, pH 9) and a peroxidase-polymer based detection kit (Histofine High Stain HRP (MULTI), REF: 414483F, Nichirei Biosciences Inc.) was employed. Diaminobenzidine (DAB) was used as the chromogen and hematoxylin as the counterstain. Stainings were carried out using an automated stainer platform (LabVision Autostainer).

The slides were scanned as high-resolution whole-slide images at a resolution of 0.16 µm per pixel (Jilab Inc., Tampere, Finland). Areas containing the strongest labeling at the lowest magnification were chosen for digital image analysis (hotspot sampling). Three to six villi covering at least 300 enterocytes were counted for IELs. Counting was done automatically using the Celiac Slide Analyzer (Jilab Inc., Tampere, Finland), which is a modification of a multi-purpose IHC cell



counting software.¹⁴ The results were reported as the number of IELs and MUC2+ cells per 100 enterocytes, or as the percentage of proliferating Cyclin B1+ crypt cells. The measurements were independent of the clinical information.

Digital histomorphometry. All slides were scanned as whole slide images using a SlideStrider scanner at a resolution of 0.28 μm per pixel (Jilab Inc., Tampere, Finland). Images were stored as JPEG2000 files in the image server and viewed *via* the internet with a web-based client software developed for this study (Celiac Slide Viewer). Villus height and crypt depth were measured digitally by drawing polylines. Two academic observers (JT, AP) analyzed all the slides independently and an average of their measurements was used as the final result for the VH/CrD ratio. During the GF challenge, a decrease in the VH/CrD of 0.5 or more was considered to be significant and equivalent to the clinical gluten sensitivity.^{13,15} CD3 positive intraepithelial T-lymphocytes were enumerated with the AutoIEL software, and the results were expressed per 100 enterocytes. After the GF challenge, an increase in the IEL counts of >30% was considered to be significant and equivalent to the clinical gluten sensitivity.¹⁵ Proliferating Cyclin B1 staining-positive crypt epithelial cells were enumerated with ImmunoRatio 2.5 software.¹⁶ For both IELs and CB1, at least 300 cells were counted.

Serology. Blood specimens drawn at the baseline, during, and at the end of the study period were analyzed using routine assays. An enzyme-linked immunosorbent assay from INOVA Diagnostics (San Diego, California, United States) was used to measure the ATTGA IgA and IgG levels, and EMA. Each serologic test was compared with its reference interval and analyzed as a binary variable (*i.e.*, elevated or not).

Cytokines. Plasma samples drawn at the baseline, during, and at the end of the study period were immediately stored at $-80\text{ }^{\circ}\text{C}$ at the CSS Hospital. The premixed multiplex beads of the Bio-Plex human cytokine Human 27-Plex Panel (Bio-Rad Laboratories, Milan, Italy), which included twenty-seven cytokines and chemokines [IL-1b; IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-10, IL-12 (P70), IL-13, IL-15, IL-17, Basic FGF, Eotaxin, G-CSF, GM-CSF, IFN- γ , IP-10, MCP-1 (MCAF), MIP-1a, MIP-1b, PDGF-BB, RANTES, TNF- α , VEGF] were used in the presence of 30 μL of plasma. All the plasma samples and standards were run in duplicate, and fluorescent signals were read using Biorad 200 system (Bio-Rad).

Intestinal permeability

Sample collection. Subjects enrolled in the study were provided with guidelines for dietary restrictions. On the morning of the test, subjects drank a solution containing 5 g of lactulose, 1 g of mannitol, and 20 g of sucrose in 200 mL of deionized water. The study subjects were then instructed to collect spot urine samples for 5 hours in a collecting bottle with 1 mL chlorhexidine (1 mg mL^{-1}) as the antimicrobial agent.

Total urine volume was measured, and 10 mL aliquots were stored at $-20\text{ }^{\circ}\text{C}$ until the analysis. The urine samples were allowed to thaw at room temperature, then stirred for 1 minute

using a vortex mixer, and then centrifuged at 5000g for 4 min to remove the sediment.

For each study participant, a 50 μL urine sample was mixed with an internal standard solution of 450 μL . In parallel, 50 μL of the control and 50 μL of the standard were each mixed with 450 μL of the internal standard solution. After mixing, a 200 μL aliquot from each of the three samples was transferred into a glass vial and injected into HPLC-MS/MS.¹¹

Instrumentation. The measurements were performed on a API 3000 Tandem Mass Spectrometer (AB Sciex, Toronto, Canada) equipped with a turbo ion spray source. Quantification was achieved using multiple reaction monitoring (MRM).

Chromatographic conditions. High-Performance Liquid Chromatography (HPLC) separation was performed using a 150 \times 2 mm, Luna 5 μm NH_2 100 \AA column (Phenomenex, USA) operating at a flow rate of 300 $\mu\text{L min}^{-1}$, and eluted with a 4 min linear gradient from 70% to 30% acetonitrile in water. The oven temperature was set at 40 $^{\circ}\text{C}$. The injection volume was 5 μL , and the total analysis time was 9 min.

Mass spectrometer conditions. The electrospray ionization (ESI) source was operated in the negative mode. The capillary voltage was set to 3500 V at a temperature of 300 $^{\circ}\text{C}$. The gas source was set as follows: nebulizer gas 8 (arbitrary units), curtain gas 7 (arbitrary units), and collision gas 4 (arbitrary units).

Each multiple reaction monitoring (MRM) transition was collected at a resolution of 0.7 amu full width half maximum (FWHM) in the first quadrupole, with a scan time of 0.1 s. The tube lens and collision settings were established individually for each compound. The conditions for the detection of lactulose, mannitol, and raffinose were obtained by the direct infusion of a standard solution (10 $\mu\text{g mL}^{-1}$), in line with the HPLC at the initial mobile phase conditions.

Method validation. In order to validate the method, the linearity, LOQ, imprecision, accuracy, recovery, and matrix effect were assessed.¹⁷ The within-run precision and accuracy ranged from 0.9% to 3.2% and from 98.0% to 102.0%, respectively. The between-run precision and accuracy ranged from 2.2% to 4.7% and from 96.2% to 101.3%, respectively.

Microbiome analysis. Fecal samples were immediately frozen by the study participants in their home freezer, inside a sterile container at $-20\text{ }^{\circ}\text{C}$, and subsequently stored at $-80\text{ }^{\circ}\text{C}$ at the CSS Hospital. Genomic DNA was extracted using the DNA powerfecal Kit (Qiagen, Hilden, Germany) following the manufacturer's recommendations. The DNA quantity was examined for each sample using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc. Somerset, USA). Microbial diversity analysis in the fecal samples was studied by sequencing the amplified V3 to V4 hypervariable region of the 16S rRNA gene on the MiSeq (Illumina, San Diego, CA, USA) platform. The PCR primers and conditions followed the Illumina 16S Metagenomic Sequencing Library preparation guide¹⁸ with the following exceptions: for the initial 16S PCR, the process was performed using Taq Phusion High-Fidelity



(Thermo Fisher Scientific) in 25 μ L reaction volumes, and 25 cycles were used in the PCR.

Subsequently, the amplicons were purified using AMPure XP beads (Beckman Coulter, Milan, Italy). Afterward, the ligation of the dual indexing adapters was performed in the presence of Nextera XT Index Primer 1 and Primer 2 (Illumina), Taq Phusion High-Fidelity (Thermo Fisher Scientific), and 5 μ L purified DNA, according to the manufacturer's instructions. The products were purified using AMPure XP beads to create the final cDNA library.

Libraries concentration and fragment size were measured using a fluorometric based system (Qubit dsDNA BR Assay System; Thermo Fisher Scientific) and an Agilent 2200 TapeStation Bioanalyzer (HS D1000, Agilent Technologies, Santa Clara, CA, USA), respectively. Equal amounts of cDNA libraries were pooled, denatured with NaOH, diluted with a hybridization buffer to 7 pM following the Illumina protocol, and spiked with 20% PhiX (Illumina). The libraries were loaded into a flow cell V2 (500 cycles) by paired-end sequencing (2×250) (Illumina), and sequenced with MiSeq (Illumina) according to the manufacturer's recommendations.

Quantification of gluten in stools. The fecal samples of the study participants were immediately frozen in home freezers, inside a sterile container at -20 °C, and subsequently stored at -80 °C at the CSS Hospital. The concentration of GIP (33-mer) in the stools was measured by a sandwich enzyme-linked immunosorbent assay (ELISA) using the iVYDAL *In Vitro* Diagnostics iVYLISA GIP-S kit (Biomedal S.L., Seville, Spain) in duplicate, following the manufacturer's guidelines. The optical absorbance was measured at 450 nm using an ELISA reader (Synergy HT, BioTek Instruments, Winooski, VT).

Symptoms' assessment. The symptoms were assessed before the trial, at weeks 4, 8, and 12 of GF administration, as well as at the end of the trial. The symptoms were noted *via* telephone using the CSI Questionnaire¹⁹ and the GSRS.²⁰ The stool frequency and consistency were registered with the Bristol Stool Chart.²¹

Statistical analysis

The subjects' sample size was pragmatic, and was calculated to assess the safety and tolerability of the GF bread while minimizing unnecessary participant exposure.

All the serum laboratory tests, namely, anti-tTG2, anti-EMA, anti-AGA antibodies, serum iron, phosphorus, folate, vitamin D3, the cytokine panel, the concentration of GIP (33-mer) in stools, the EMA in the biopsies, and the lactulose/mannitol ratio in urine were evaluated by comparing the studied time points (Fig. 1). All the statistical tests were performed through Statistica for Windows, ver. 12.0 software (Statsoft, Tulsa, OK, USA).

The values of VH/CrD, cytokines (2, 4, 6, 8, IFN, TNF), IELs, MUC2, CB1, 33-mer detection, and antibodies were analyzed by means of one-way analysis of variance (ANOVA) and Tukey's test. If data distribution did not show a normal trend, the values were analyzed through the non-parametric Friedman test. The critical level of P was set to 0.05. Here, we shown only

statistically significant results or those with a clear involvement in the CD pathogenesis (to note, although all the panel was analyzed, only the cytokines named 2, 4, 6, 8, IFN, and TNF were shown).

Symptoms. CSI results were analyzed through the non-parametric Friedman test ($P < 0.05$). Study groups (A, B, or C) and time (immediately before the trial, at weeks 4, 8, and 12, as well as after the trial) were used as categorical predictors.

K-means and second statistical analysis. VH/CrD, IELs, MUC2, CB1, and 33-mer detection were used as the input variables to run the k-means analysis. MUC and CB1 were preliminarily standardized as the increase (%) after the trial, as follows.

$$I(\%) = \frac{E - B}{B} \times 100$$

where E is the value at the end of the trial, and B is the value at the beginning; 33-mer detection was reported as the percentage of subjects with a negative G12 (*i.e.*, subjects where 33-mer was not detected).

For K-means clustering, the parameter K (number of cluster) was set to 3, while the interactions were at least 10. The initial inter-cluster centers were evaluated by sorting the distance and taking observations at constant intervals.

Microbiota analysis. Short reads obtained with Illumina MiSeq sequencing were quality-checked using FastQC²² and SolexaQA.²³ All the samples passed the default quality thresholds, and no truncation on either end was deemed necessary. The reads were subsequently processed by standard QIIME2 v.2018.6 pipeline.²⁴

Preparation was done using DADA2²⁵ and included denoising, chimera checking, pair-joining, and clustering through dereplication. Taxonomic classification, from the domain to the genus, was obtained through the embedded Naïve Bayes fitted classifier, trained on the Silva release.132 rRNA database.²⁶ All the samples were then rarefied based on the outcomes of the feature table produced during the preparation phase. Any possible loss of information was ruled out by the examination of the rarefaction plots.

Alpha and Beta diversity analyses were performed in order to assess both within-sample and between-sample diversity, using several metrics. In particular, Faith's Phylogenetic Diversity index was investigated for Alpha diversity, and was tested using the Kruskal-Wallis test. Unweighted UniFrac distance was used to build a PCoA plot for Beta diversity, and was tested using the PERMANOVA test.²⁷ Finally, the ANCOM abundance test²⁸ was applied at the genus level in order to identify the features that were differentially abundant across the sample groups.

The readings of each genus, family, or species were modelled as the recovery detection (%) on the total number of reading for each subject; then, the changes in the recovery detection were evaluated as the difference between the recovery after trial and the recovery before trial. These values were analyzed through the Friedman test ($P < 0.05$) to highlight the significant differences ($P = <0.05$).



Combined index of the proinflammatory microbiota. The index of the proinflammatory microbiota was evaluated by combining *Slackia* and *Sutterella* detection; in the K-means clusters (K1, K2, sub-cluster K3 “Friendly”, and sub-cluster K3 “Free”), each subject was assigned a code as follows: 0, if *Slackia* and *Sutterella* were not detected; 50%, if only a genus was detected; 100%, if both the genera were detected. The scores were summed up and divided by the number of subjects in each cluster. The statistical differences among the clusters were pointed out through the chi-square test ($P < 0.05$).

Results and discussion

Between April and September 2017, 67 celiac subjects were recruited and forty-eight were enrolled in a 12-week therapeutic intervention study (Fig. 1) after the informed consent form was signed and approved from the local Ethics Committee (N.46/CE). 19 subjects were excluded for these reasons: CD dismissed ($n = 6$), presence of TGA ($n = 8$), and no compliance ($n = 5$). The subjects ranged from 15 to 75 years of age, with a mean age of 38 years (Table 1). Patients randomized into 3 groups at 100 g of bread daily, containing different doses of GF. Group A (11 subjects) received 0 g; Group B (19 subjects) received 3 g; and group C (18 subjects) received 6 g (Fig. 1). All the patients completed the study. The strict monitoring of a gluten-free diet (GFD) was imposed throughout the trial.

Gluten Friendly™ does not induce symptoms in celiac subjects

Gastrointestinal symptoms from mild to severe can occur frequently in patients with untreated celiac disease. A life-long

GFD can significantly improve gastrointestinal conditions but symptoms may not completely disappear.

Gluten challenge studies have shown that celiac patients experience a rapid, dose-dependent surge of symptoms when gluten is reintroduced in their diet.^{15,29} In this research, the symptoms were evaluated through two different methods, *i.e.*, Celiac Symptoms Index Questionnaire (CSI) and the Gastrointestinal Symptom Rating Scale (GSRS). The CSI results are shown in Fig. 2 as a box-plot graphs due to the non-parametric distribution of data. CSI scores (Fig. 2) did not differ significantly at the baseline, thus confirming the homogeneity among the groups (A, B, and C). However, the symptoms were reported in all the groups in spite of the CD subjects following a GFD for a minimum of two years, as suggested by the median and quartile ranges in the three groups: 31 with an interquartile range from 22 to 40. After 4 weeks, all the subjects experienced a significant decrease in the CSI scores ($P < 0.05$, Friedmann test) and remained at their lowest value throughout the study, with a median value of 16–19 for 12 weeks (Fig. 2). This significant decrease, as evidenced by the Friedman test, could be due to different reasons: in control group A, it could be a result of the study protocol. Strict monitoring of the GFD, in fact, was imposed on all the groups (A, B, C) throughout the 12 weeks of the trial because patients were tested weekly through a Biocard Celiac Test for the rapid screening of the levels of anti-tissue transglutaminase IgA antibodies. On the other hand, in groups B and C, there was clearly an effect of GF eating, thus suggesting the possible effect of GF on symptoms' recovery and the possible action on symptoms' relief.

After the trial, the CSI scores increased, although the levels were lower than on week 0 of the study (Fig. 2). Such relapse in the symptoms could be a result of gluten ingestion, either deliberate or inadvertent, while on a GFD³⁰ since this diet is

Table 1 Characteristics of randomized patients with celiac disease

	Placebo	3.0 g	Gluten friendly 6.0 g
N of patients	11	19	18
Female	7	11	10
Age in years, mean (ds)	38.6 ± 21.1	35.0 ± 15.3	39.1 ± 15.1
<20	3	3	3
20–49	5	11	10
≥50	3	5	5
Measurement			
Height, means (SD) in cm	168.5 ± 9.4	168.9 ± 9.6	168.4 ± 10.1
BMI mean (SD)	21.7 ± 2.4	22.8 ± 3.8	23.5 ± 3.1
<20	2	4	2
20–24.9	9	11	9
25–29.9		3	6
≥30		1	1
Duration of GFD in years			
Mean (SD)	8.6 ± 6.2	12.3 ± 6.6	11.6 ± 9.1
1–1.9	0		0
2–3.9	2	1	3
4–5.9	2	4	4
6–7.9	2	2	1
>8	5	12	10
HLA			
DQ2	9 (82%)	16 (84%)	17 (94%)
DQ8	1 (9%)	0 (0%)	1 (6%)
DQ2–DQ8	1 (9%)	3 (16%)	0 (0%)




Fig. 2 Gluten friendly induces symptoms relief the box-whisker plot indicates CSI scores for the three trial groups (a, control group/gluten free group; b, 3 g of GF daily; c, 6 g of GF daily). Lower case letters (a; b; a,b) indicate significant differences (Friedmann test, $p < 0.05$).



socially troublesome, expensive, and compliance is problematic.

As reported above, the symptoms were also assessed through GSRS, which is based on a different prerequisite. With this second assessment, the symptoms were not recorded in line with the Bristol Stool Chart data of normal stool consistency (ESI Table 1†).

After 12 weeks of Gluten Friendly, the results show an uncoupling between the mucosal injury and inflammation in celiac subjects

Gluten-induced small intestinal mucosal injury is the gold standard for diagnosing celiac disease.³¹ During a gluten challenge, an inflammatory process with a dose-dependent accumulation of intraepithelial lymphocytes (IELs) is followed by villous atrophy with crypt hyperplasia.³²

Crypt hyperplasia is associated with an increased turnover of epithelial cells, marked by a higher expression of Cyclin B1 (CB1).³³ Gut barrier permeability is altered with the infiltration of cytotoxic T-cells in the lamina propria.³⁴ The total number of goblet cells producing Mucin 2 (MUC2) in the duodenal mucosa is reduced.³⁵

To investigate the effects of GF on mucosal histology and inflammation, we analyzed small-bowel morphology (VH/CrD), intraepithelial densities of CD3+, celiac serology, *i.e.*, EMA (anti-endomysium antibodies) and TGA (anti-transglutaminase antibodies), MUC2, CB1, gut barrier permeability, and a panel of proinflammatory cytokines. The absence/presence of the 33-mer gluten peptide in stools was assessed through the G12-ELISA immunoassay.

Duodenal mucosal deterioration was significant in groups B and C, compared to the placebo group A (Fig. 3a). However, the boxes and plots suggest a strong variability within each

group. The median values of IELs at the end of the trial (Fig. 3b) were 26%, 38%, and 57% for groups A, B, and C, respectively; however, the differences among the groups were not significant and the box-plots suggest a strong variability within all the groups.

MUC2 and CB1 were analyzed by one-way ANOVA (ESI Fig. 1 and 2†). The differences among the groups were not significant and each group showed high variability. We recorded similar findings for our cytokine panel (IL-2, IL-4, IL-6, and IL-8), TNF- α , and IFN- γ (ESI Fig. 3 and 4†).

EMA and TGA antibodies were never detected in the subjects from the placebo group A. In the GF groups, seroconversion occurred in 15% (B) and 47% (C) of the subjects after 4 weeks, which further increased to 42% (B) and 68% (C) after 12 weeks.

We utilized G12/33-mer assay to detect gluten in stools because this assay is generally used to assess if celiac patients consume gluten. The results are in Fig. 4 and are reported on a qualitative basis (presence/absence of 33-mer in the stool). As expected, due to the consumption of a gluten free-diet, 33-mer was always lacking on the stools of the patients of group A, while the 33-mer peptide in the stool samples was below the detection limit (absence) in 8 patients from group B, corresponding to 47% of the total. In the group C, 33-mer was below the detection limit in 10 subjects (55% of the total).

In some patients, 33-mer was not detectable due to a technical issue (3 from B and 3 from C groups).

As a consequence, we could not establish the expected correlation between 33-mer detection and serology, nor between 33-mer detection and mucosal injury. Rather, we found partial uncoupling between the 33-mer peptide and both VH/CrD and antibodies.

We expected VH/CrD to correlate strongly with an increase in the IELs, an increase in the CB1, and a decrease in MUC2.




Fig. 3 VH/CrD and IEL at the end of trial in groups A, B and C. A, 0 g of GF daily; B, 3 g of GF daily; C, 6 g of GF daily. Morphometric analysis (A) measuring VH/CrD was made in well-oriented biopsy samples. A decrease in VH/CrD of 0.5 or more was considered significant and equivalent to clinical gluten sensitivity. Immunohistochemistry (B) of IELs was carried out through anti-CD3 antibody. An IEL increase of more than 30% was considered significant and equivalent to clinical gluten sensitivity. Measurements were independent of clinical information.






Fig. 4 Detection of 33-mer peptide at the end of trial in groups A, B and C. A, 0 g of GF daily (control group); B, 3 g of GF daily; C, 6 g of GF daily. White indicates no 33-mer detection (NO); dark grey indicates 33-mer detection (YES); light grey indicates insufficient material during sampling (insufficient material). The number on the bars indicate the subjects per each class (NO; YES; insufficient material).

Though there was a decrease in MUC2, VH/CrD was unrelated and uncoupled with both IELs and CB1. The partial correlation of VH/CrD with TG2 and EMA in our results was expected as it has been found that serum TG2 and EMA often underestimate the degree of VH/CrD.³⁶

Finally, we expected VH/CrD to strongly correlate with an increase in the gut permeability and proinflammatory cytokines,³⁷ which can disrupt the proteic components of tight junctions (TJs).³⁸ However, gut permeability did not support

this hypothesis; in fact, the differences between the gut permeability amongst the groups A, B, and C were not significant both before and at the end of the trial; in addition, the differences between the data before and after the trial were not significant (ESI Fig. 5,†), suggesting that GF did not cause the opening of TJs, in contrast to the CD literature. These results are in line with previous *in vitro* studies, where GF flour showed the ability to increase TEER in human intestinal goblet cells.¹⁰

Overall, the data suggested an uncoupling between VH/CrD and IEL, CB1, cytokines, gut permeability, and 33-mer detection in stools. While histology was consistent with well-established gluten challenge literature, all the subjects showed a high variability of data in some key parameters, eluding the strong two-class correlations that are usually established within the framework of untreated celiac disease.

Clustering through K-means shows an uncoupling of mucosal injury, inflammation markers, and 33-mer peptide detection

The new hypothesis that the subjects clustered around the “unknown variables” emerged. Therefore, we approached the data as a whole, regardless of the GF dosage. We searched for major factors at play through K-means analysis (Fig. 5) (ESI Tables 2 and 3†).

K was set to 3 to reflect the number of groups in the study (A, B, C) and to avoid statistical artifacts. The input variables were VH/CrD, IEL, MUC2, CB1, and 33-mer. The permeability and cytokines were excluded as they did not present significant




Fig. 5 Clustering through K-means shows an uncoupling of mucosal injury, inflammation markers and 33-mer peptide detection parameters above show mean values for VH/CrD decrease (A), MUC2 decrease (B), CB1 increase (C), IELs increase (D), and 33-mer peptide detection in K-means clusters. In (A), (B) and (D), bars represent 95% confidence intervals, whereas letters denote significant differences (one-way anova or Friedmann test). In (C) and (E), asterisks denote clusters belonging to homogeneous groups (one-way anova). K1, K2 and K3: clusters 1, 2 or 3 of K-means.






Fig. 6 Presence of pathobionts in cluster 1 and 2. Figures above show the recovery of *Slackia* and *Sutterella* in the faecal microbiota of celiac subjects at the beginning of trial, distributed in K-means clusters and sub-clusters (A), and the standardized score of pro-inflammatory genera evaluated as the sum of *Slackia* and *Sutterella* (B). K1, K2 and K3: clusters 1, 2 or 3 of K-means. The word friendly and free indicate the sub-cluster of cluster 3 and the subjects receiving GF bread and gluten free bread.

increase in Proteobacteria might contribute to nonspecific mucosal inflammation due to lipopolysaccharide (LPS) stimulation, and possibly predispose the host to a chronic inflammatory disease.⁴³ *Slackia* has been associated with a variety of imbalances, in particular, microbial dysbiosis connected to gastric carcinogenesis.⁴⁴

In our analysis, *Sutterella* was found in 66.67% of subjects in K1 and 40% of subjects in K2. In K3, recovery detection was significantly lower in both the “Friendly” (15.38%) and “Free” (28.57%) sub-clusters (Chi-square test, $P < 0.05$). *Slackia* was not found in any of the subjects in K3. The recovery detection was 16.67% in K1 and 60% in K2.

Recent studies have highlighted the role of gut microbes in determining the gluten immunogenicity. It has been shown that

pathobionts such as *P. aeruginosa* isolated from CD patients cleaved the 33-mer peptide in such a manner that it activated gluten-specific T-cells. At the same time, the peptides could be further metabolized by duodenal *Lactobacillus* spp. to lose their immunogenicity.⁴⁵ Different inflammatory pathways in the intestinal mucosal surface are activated by exposure to infectious agents that compete with beneficial microbes to adhere to the intestinal mucosa and disturb intestinal barrier function.⁴⁰ A disturbed intestinal barrier leads to the exposure of intestinal immune cells to dietary antigens (*i.e.*, gluten). Conversely, a healthy microbial ecology—defined as a balance between beneficial bacteria, harmful bacteria, and beneficial microbes—prevents the activation of inflammatory pathways and favors immune cell tolerance.⁴⁶

Based on this literature, our hypothesis is that *Slackia* and *Sutterella* could jointly contribute to a proinflammatory response and interfere with the digestion of GF in celiac subjects. In order to assess their synergistic additive effect, we designed an arbitrary index. A ternary code was assigned to each subject: 0, when both *Slackia* and *Sutterella* were not detected; 50%, when only one genus was found; 100%, when both *Slackia* and *Sutterella* were found (ESI Table 4†).

The results of this index, called “standardized score of proinflammatory genera”, are shown in Fig. 6b. The score was 41.67% in K1 and 40% in K2. Instead, in K3, the score was significantly lower in both the “Friendly” (11.54%) and in the “Free” (14.29%) subclusters ($P < 0.05$, Chi-square test).

The different recovery of *Slackia* and *Sutterella* found in the stool samples of the celiac subjects at the baseline strongly correlated with the presence/absence of 33-mer in the K-means clusters (end of the study), *i.e.*, the almost total absence of the 33-mer peptide in K3 and its significant presence in K2 and K1 (ESI Table 2†).

Therefore, it can be postulated that *Slackia* and *Sutterella* interfered with the digestion of GF in 53% of celiac subjects in K1 and 27% of celiac subjects in K2, where 33-mer was detected. Furthermore, *Slackia* and *Sutterella* may have predisposed the intestines to inflammation even in the remaining celiac subjects from K1 and K2, where 33-mer was not detected. Such hypothesis seems to be corroborated by the uncoupling between VH/CrD decrease and 33-mer presence in K1 and K2. Our hypothesis is that in the presence of *Slackia* and *Sutterella*, even traces of the 33-mer peptide (below 40 ppm) not detectable by G12 immunoassay could cause detrimental effects on the gut mucosa. This is in line with previous studies, highlighting how celiac sensitivity to very low amounts of gluten may vary depending on the intestinal microenvironment.⁴⁷

Conversely, in the presence of a healthy microbial ecology, as observed in the subjects in the K3 “Friendly” sub-cluster (Fig. 6), butyrate-producing species were able to thrive and celiac gut microbiota endopeptidases were able to digest GF without detrimental effects on celiac gut mucosa.

Gluten Friendly shapes celiac microbiota toward intestinal homeostasis

The last step of this research was to focus on how GF administration affected the microbiota over time. Our analysis evi-






Fig. 7 Gluten friendly shapes gut microbiota towards homeostasis. Figures above show changes (increase or decrease of abundance at the end of the trial) in the relative abundance (%) of *Agathobacter* spp. (A), *Eubacterium coprostanoligenes* spp. (B), *Tyzzerella* spp. (C), *Lactobacillus* spp. (D) and *Intestinimonas* (E) after 12 weeks of trial. K1, K2 and K3: clusters 1, 2 or 3 of K-means. the word friendly and free indicate the sub-cluster of cluster 3 and the subjects receiving GF bread and gluten free bread.

denced significant variations in the recovery of the following bacteria: *Agathobacter* spp (Fig. 7a), *Eubacterium coprostanoligenes* (Fig. 7b), *Tyzzerella* spp (Fig. 7c), *Lactobacillus* spp (Fig. 7d), and *Intestinimonas* spp (Fig. 7e). The data should be read as recovery variation (increase or decrease) after 12 weeks. The data is reported as the box-plot pictures with medians and quartiles as it is not possible to assume that they follow a normal distribution.

Fig. 7a shows the changes in the recovery of *Agathobacter* spp. Cluster K1 evidenced a median value of -0.27% , while the 3rd and 1st quartiles were 0 and -1.25% (box), respectively, with a minimum value of -3.1% . Such distribution suggests that celiac subjects in K1 (at least 75% of them) experienced a decrease in the *Agathobacter* spp. population after 3 months. A similar trend was found in K2, where the median value of variation was 0%, 3rd and 1st quartiles of respectively 0% and -0.8% , with a minimum value of -2.1% . In K3, the “Friendly” data evidenced a significant difference. The median value was 0.4% . The 1st and 3rd quartiles were 0 and 0.8% , respectively, with a maximum value of 4.3% . The range from the 1st quartile to maximum ($0-4.3\%$) suggests that for this cluster, 75% of the subjects in K3 “Friendly” experienced an increase in *Agathobacter* spp.

Fig. 7b shows the recovery variation of *Eubacterium coprostanoligenes*. The recovery variation was not significant. K1 experienced a strong variation, while the box of K3 “Friendly” (median, 1st, and 3rd quartiles around 0%) suggested a possible homeostasis for at least 50% of the celiac subjects.

Eubacterium coprostanoligenes is an anaerobic, Gram-positive coccobacillus with cholesterol-reducing properties.⁴⁸

Fig. 7c shows the recovery variation of *Tyzzerella* spp., evidencing homeostasis for both K3 “Friendly” and “Free” clusters (box, maximum, and median to 0%), while K1 and K2 clusters evidenced a significant variation with an increasing trend; the differences between the “Friendly”/“Free” clusters and K2/K1 clusters were significant ($P, 0.0488$). Previous studies have linked distinct *Tyzzerella* species to the inflammatory milieu of Crohn’s Disease and functional gastrointestinal disorders in autistic children,⁴⁹ respectively.

Fig. 7d shows the recovery variation of *Lactobacillus* spp., showing an increase ($P, 0.0217$) in K2 (median and 1st quartile 0.03% ; 3rd quartile, 0.15% ; maximum, 1.0%).

Fig. 7e shows the recovery variation of *Intestinimonas* spp., showing an increasing trend in K1.

Lactobacillus is a well-known genus with various beneficial properties. It can contribute to gut re-equilibration and to shape the microbiota toward homeostasis, with a protective effect against inflammation. Moreover, *Lactobacillus* spp. might promote the homeostasis of the gut mucus layer through L-Ornithine (L-Orn) production. L-Orn stimulates L-tryptophan (Trp) metabolism to produce aryl hydrocarbon receptor (AhR) ligands in the gut epithelial cells, which induce the accumulation of ROR γ t(+) IL-22(+) ILC3 in the gut tissues.⁵⁰

Significant variations of *Lactobacillus* spp. in the microbiota of celiac subjects, as observed in cluster K2, confirmed the



in vivo bifidogenic effect of GF. In fact, in previous studies,^{8,9} GF has shown its *in vitro* ability to stimulate both *Lactobacilli* growth and metabolism. Significant *Lactobacillus* spp. increase could play a role in the unexpected uncoupling between VH/CrD vs. IELs and VH/CrD vs. 33-mer in K2, after 12 weeks of eating GF. This could also explain why celiac subjects experienced a consistent relief in the symptoms. Although the data on microbiota variations (Fig. 7d) show that K2 was not in homeostasis, it could be hypothesized that the *Lactobacilli* were metabolizing GF and exploiting it as a source of energy. In turn, *Lactobacilli* metabolism contributed to taming the inflammation. Studies have suggested that gut commensals, including *Lactobacillus*, *Bifidobacterium*, *Bacteroides*, *Clostridium*, and *Streptococcus*, as well as bacterial metabolites such as butyric acid and propionic acid, may program Treg cells in the intestine toward tolerogenicity, helping the host with the maturation and homeostasis of the immune system.⁵¹

Furthermore, the increase in *Intestinimonas* and *Agathobacter* in both K1 and the K3 “Friendly” cluster, seems to point in the same direction. Both the species produce butyrate, contributing to a “healthy ecology” of the gut and to its homeostasis. *Agathobacter* uses acetate to produce butyrate,⁵² while *Intestinimonas* grows by metabolizing amino acids, in particular, lysine and glutamate, and produces butyrate.⁵³

Overall, these results confirm the hypothesis beyond clustering: time may be a crucial factor in enabling GF interaction with celiac gut mucosa by reshaping its microbiota toward homeostasis. The idea of a re-shaping, or at least beginning a reshaping, was supported by an overview of all the data of microbiota composition, at least for the most important genera for CD (ESI Table 5†). As reported elsewhere, the data did not follow a parametric distribution; therefore, the information was synthesized through position indices (median, quartiles, minimum, and maximum). A check of the quantitative composition for 54 genera/groups suggests for some of them a re-shaping from the beginning to the end of the trial; this information was also reported in ESI Fig. 6 and 7,† which reports the median values for all the genera.

For some genera, the figures show a shift in the median values to higher or lower values compared to the beginning for most. Sometimes, the differences were significant, while for other genera, there was a shift in the median and quartiles, while the maximum and minimum of distribution were not affected probably due to some subjects that did not experience a shift or restoration of the microbiota, for example, *Alistipes*, *Blautia*, (in ESI Fig. 6 part A;† the genera correspond to the numbers 10 and 20), *Lachnoclostridium*, *Faecalibacterium*, *Escherichia/Shigella* (in ESI Fig. 6 part B;† the genera correspond to the numbers 25, 39, 53). For other genera, there was a significant shift at least for the inter-quartile range; as an example, ESI Fig. 7† shows the results for *Eisenbergiella* (part A) and for *Saccharimonadaceae* (part B).

The chart of *Eisenbergiella* confirms our hypothesis reported for *Slackia* and *Sutterella*; the initial printing of the microbiota in terms of the pro-inflammatory and beneficial microorganisms could affect the response to GF. At the baseline, the median and quartile 1 of cluster 1 were 0.0% and the quartile 3 was 0.053%, thus suggesting that *Eisenbergiella* was almost missing in at least 75% of the subjects of this cluster; on the other in cluster 3, at the baseline, the median was 0.109%, quartile 3 at 0.795%, and the maximum of the distribution was 1.376%, thus highlighting a relatively higher abundance in the subjects of cluster 3 receiving GF. Another interesting evidence was the trend of K2, which showed an intermediate trend between K1 and K3.

Eisenbergiella is probably related to eubiosis because it can produce butyrate, acetate, lactate, and succinate as major metabolic products, with a trophic effect on the mucosa.⁵⁴ Its higher abundance in K3 and K2 subjects should be read in an opposite way of *Slackia*: while the latter genus is a marker of pro-inflammatory conditions, *Eisenbergiella* could be a marker of a possible positive effect of GF.

Fig. S7B† shows the shift in *Saccharimonadaceae* and the different trends between cluster 1 (K1) and cluster 3 (K3); for this family, GF exerted a modulating effect with a strong reduction after the trial in cluster 3 receiving Gluten Friendly, as suggested by median and quartile 3, both of which were 0.0% (family lacking in at least 75% of subjects). The role of *Saccharimonadaceae* was not clear but a recent evidence suggests a correlation of this family with inflammatory responses and high reactions of the immune system.⁵⁵

Gut microbiota is a complex entity, composed of bacteria, fungi, and viruses; in this research, we have addressed only the effect of GF on the bacteria because of the preliminary experiments and their evidence on some target genera (such as *Lactobacillus* and *Bifidobacterium*). However, the fungi could also play a role in the modulation of the gut microbiota and on its positive or negative shifts; therefore, further investigations are required in the future to address this issue.

Conclusion

Gluten friendly has shown *in vivo* unprecedented characteristics that elude well-established literature on the gluten challenge. All 37 celiac subjects eating 3 g (Group B) or 6 g (Group C) of GF for 12 weeks experienced no symptoms or even an improvement of symptoms, according to CSI scores and GSRS. The 33-mer gluten peptide could not be found or was undetectable in 24 celiac subjects eating GF, suggesting the possibility of digestion. Based on histology and antibody sero-conversion, GF appeared to be disease-inducing in a majority of study subjects over the course of 12 weeks. However, the GF data set did not show strong correlations typical of gluten-induced mucosal damage. For example, VH/CrD did not correlate with IELs >30%, 33-Mer in stools, and the symptoms. K-means analysis evidenced the possibility of celiac subjects



clustering (K1, K2, K3) around unknown parameters independent of the GF dosage. Recent studies have highlighted the role of gut microbes in determining the gluten immunogenicity. The microbiota variations of specific proinflammatory (*Slackia* and *Sutterella*) and healthy and butyrate-producing bacteria (*Lactobacillus* spp, *Agathobacter* spp, and *Intestinimonas* spp) evidenced a correlation with the K-means clustering of celiac subjects, namely, lack of symptoms, no 33-mer detection, and IELs <30%. Proinflammatory gut ecology showed an adverse role in the digestion and tolerance of GF in the study subjects. However, our research suggests that GF shapes the microbiota toward gut homeostasis in celiac subjects by boosting healthy butyrate-producing populations. Time may be a crucial factor in enabling GF to immunomodulate the celiac gut mucosa, along with the initial composition of the microbiota. This result will be shared in the future with volunteers and subjects involved in other studies because our feeling is that further experiments are required to elucidate the mode of action of GF, its modulatory effect on the microbiota, the reasons for the uncoupling between the mucosal data, and other evidences (symptoms, IEL, and gluten tolerance).

Apart from the results, another conclusion of this research is that, although not clinically validated yet, the qualitative composition of the microbiota should be considered for such situations, such as CD.

Author contributions

Design research: Carmen Lamacchia, Angelo Andriulli, Antonio Bevilacqua, Orazio Palmieri and Maria Rosaria Corbo; Methodology: Carmen Lamacchia, Angelo Andriulli, Antonio Bevilacqua, Orazio Palmieri, Maria Rosaria Corbo and Milena Sinigaglia; Software: Antonio Bevilacqua, Orazio Palmieri, Michele Tricarico, Leonardo Petruzzi; Validation: Antonio Bevilacqua, Orazio Palmieri, Carmen Lamacchia; Formal analysis: Antonio Bevilacqua, Orazio Palmieri, Stefano Castellana, Tommaso Mazza and Leonardo Petruzzi; Conducted research: Orazio Palmieri, Anna Latiano, Rosanna Fontana, Domenica Gioffreda, Anna Panza, Claudia Menzaghi, Elvira Grandone, Lazzaro di Mauro, Ivana Decina, Michele Tricarico, Daniela Musaico, Alina Popp, Juha Taavela, Leonardo Petruzzi; Resources: Angelo Andriulli, Carmen Lamacchia, Markku Maki, Jorma Isola; Data curation: Angelo Andriulli, Orazio Palmieri, Antonio Bevilacqua and Carmen Lamacchia; Writing-original draft: Carmen Lamacchia, Antonio Bevilacqua and Maria Rosaria Corbo; Writing - review & editing: Carmen Lamacchia, Antonio Bevilacqua, Maria Rosaria Corbo, Milena Sinigaglia, Angelo Andriulli, Orazio Palmieri, Markku Maki, Jorma Isola, Juha Taavela and Daniela Musaico; Visualization: Carmen Lamacchia, Antonio Bevilacqua, Maria Rosaria Corbo; Supervision: Angelo Andriulli and Carmen Lamacchia; Project administration: Carmen Lamacchia and Angelo Andriulli; Funding acquisition: Carmen Lamacchia.

Data and materials availability

All data is available in the main text or the ESI.† The raw data that is presented in this paper is available upon request from Ospedale Casa Sollievo della Sofferenza in San Giovanni Rotondo, Italy, without restrictions.

Conflicts of interest

Angelo Andriulli, Orazio Palmieri, Anna Latiano, Rosanna Fontana, Domenica Gioffreda, Stefano Castellana, Tommaso Mazza, Anna Panza, Claudia Menzaghi, Elvira Grandone, Lazzaro di Mauro, Markku Mäki, Jorma Isola, Alina Popp, Juha Taavela declare no competing interest; Ivana Decina and Michele Tricarico declare that their institution has a patent related to this work: “Method for detoxification of gluten proteins from grains of cereals and related medical uses” (Italian Priority Patent No. 102015000084813, Patent Cooperation Treaty PCT/EP2016/0815899, 2016). Daniela Musaico, Antonio Bevilacqua, Leonardo Petruzzi, Milena Sinigaglia, Maria Rosaria Corbo declare that their institution has a patent related to this work: “Method for detoxification of gluten proteins from grain of cereals” (Patent Cooperation Treaty PCT/IB2013/000797, 2013); Carmen Lamacchia declares that she is a founder and a share holder, at about 60%, of New Gluten World s.r.l since april 2015. She serves as a CEO of the New Gluten World since April 2015. She is the inventor of the following patents related to this work: “Method for detoxification of gluten proteins from grain of cereals” (Patent Cooperation Treaty PCT/IB2013/000797, 2013) and “Method for detoxification of gluten proteins from grains of cereals and related medical uses” (Italian Priority Patent No. 102015000084813, Patent Cooperation Treaty PCT/EP2016/0815899, 2016).

Acknowledgements

We thank all celiac volunteers and their families for participating in this study, as well as the physicians, nurses, and medical staff who helped with recruitment at Fondazione IRCCS Casa Sollievo della Sofferenza Hospital. We thank the following individuals for their support and assistance throughout the study: Corritore Giuseppe, Gentile Annamaria, Tiziana Latiano, Ercolino Filomena, Antonio Ippolito, Fulvio Spirito, Marco Gentile, Francesco Perri, Lucia Salvemini, Gennaro Vecchione, Mauro Truglio and Giuseppe Cappucci. Additional thanks to Storyhatch Srls for supporting the manuscript with editing and proof-reading. Obtained funding: This research was accomplished with the financial support of Casillo Group S.p.a. (Corato, Italy). This project has also received funding from the European Union's Horizon 2020 research and innovation program, under grant agreement no. 732640. Disclaimer: the contents of this publication are the sole responsibility of the authors, and do not necessarily reflect the opinion of the European Union.



References

- I. Nadal, E. Donat, C. Ribes-Koninckx, Y. Calabuig and M. Sanz, Imbalance in the composition of the duodenal microbiota of children with coeliac disease, *J. Med. Microbiol.*, 2007, **56**, 1669–1674.
- G. Marasco, A. R. Di Biase, R. Schiumerini, L. H. Eusebi, L. Iughetti, F. Ravaioli, E. Scaioli, A. Colecchia and D. Festi, Gut microbiota and celiac disease, *Dig. Dis. Sci.*, 2016, **61**, 1461–1472.
- E. Sánchez, E. Donat, C. Ribes-Koninckx, M. Calabuig and Y. Sanz, Intestinal Bacteroides species associated with coeliac disease, *J. Clin. Pathol.*, 2010, **63**, 1105–1111.
- K. A. Bascuñán, M. Araya, L. Roncoroni, L. Doneda and L. Elli, Dietary gluten as a conditioning factor in celiac disease, *Adv. Nutr.*, 2020, **11**, 160–174.
- C. Lamacchia, L. Landriscina and P. D'Agnello, Changes in wheat kernel proteins induced by microwave treatment, *Food Chem.*, 2016, **197**, 634–640.
- C. Lamacchia, A. Di Luccia and C. Gianfrani, Method for the detoxification of gluten proteins from grains of cereals, *Patent Cooperation Treaty PCT/IB2013/000797*, 2015.
- L. Landriscina, P. D'Agnello, A. Bevilacqua, M. R. Corbo, M. Sinigaglia and C. Lamacchia, Impact of Gluten-Friendly™ technology on wheat kernel endosperm and gluten protein structure in seeds by light and electron microscopy, *Food Chem.*, 2017, **221**, 1258–1268.
- A. Bevilacqua, A. Costabile, T. Bergillos-Meca, I. Gonzalez, L. Landriscina, E. Ciuffreda and C. Lamacchia, Impact of Gluten-Friendly bread on the metabolism and function of in vitro gut microbiota in healthy human and coeliac subjects, *PLoS One*, 2016, **11**, e0162770.
- A. Costabile, T. Bergillos-Meca, L. Landriscina, A. Bevilacqua, I. Gonzalez-Salvador, M. R. Corbo, L. Petruzzi, M. Sinigaglia and C. Lamacchia, An in vitro fermentation study on the effects of Gluten Friendly™ bread on microbiota and short chain fatty acids of fecal samples from healthy and celiac subjects, *Front. Microbiol.*, 2017, **8**, 1722.
- C. Lamacchia, D. Musaico, M. E. Henderson, T. Bergillos-Meca, M. Roul, L. Landriscina, I. Decina, G. Corona and A. Costabile, Temperature-treated gluten proteins in Gluten-Friendly™ bread increase mucus production and gut-barrier function in human intestinal goblet cells, *J. Funct. Foods*, 2018, **48**, 507–514.
- J. Gervasoni, A. Schiattarella, V. Giorgio, A. Primiano, C. Russo, V. Tesori, F. Scaldaferrri, A. Urbani, C. Zuppi and S. Persichilli, Validation of an LC-MS/MS method for urinary lactulose and mannitol quantification: results in patients with irritable bowel syndrome, *Dis. Markers*, 2016, **2016**, 5340386.
- C. Lamacchia, Method for detoxification of gluten protein from grains of cereals and related medical uses, *Italian priority patent no 102015000084813*, Patent Cooperation Treaty PCT/EP2016/0815899, 2016.
- J. Taavela, O. Koskinen, H. Huhtala, M. L. Lähdeaho, A. Popp, K. Laurila, P. Collin, K. Kaukinen, K. Kurppa and M. Mäki, Validation of morphometric analyses of small-intestinal biopsy readouts in celiac disease, *PLoS One*, 2013, **8**, e76163.
- V. J. Tuominen and J. Isola, Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol, *J. Digital Imaging*, 2010, **23**, 454–462.
- M. L. Lähdeaho, M. Mäki, K. Laurila, H. Huhtala and K. Kaukinen, Small-bowel mucosal changes and antibody responses after low- and moderate-dose gluten challenge in celiac disease, *BMC Gastroenterol.*, 2011, **11**, 129.
- V. J. Tuominen, S. Ruotoistenmäki, A. Viitanen, M. Jumppanen and J. Isola, ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67, *Breast Cancer Res.*, 2010, **12**, R56.
- J. Gervasoni, A. Primiano, C. Graziani, F. Scaldaferrri, A. Gasbarrini, A. Urbani and S. Persichilli, Validation of UPLC-MS/MS method for determination of urinary lactulose/mannitol, *Molecules*, 2018, **23**, 2705.
- 16S metagenomic sequencing library preparation, 2013, https://support.illumina.com/documents/documentation/chemistry_documentation/16s/16s-metagenomic-library-prep-guide-15044223-b.pdf.
- D. A. Leffler, M. Dennis, J. E. George, S. Jamma, E. F. Cook, D. Schuppan and C. P. Kelly, A validated disease-specific symptom index for adults with celiac disease, *Clin. Gastroenterol. Hepatol.*, 2009, **7**, 1328–1334.
- D. A. Revicki, M. Wood, I. Wiklund and J. Crawley, Reliability and validity of the Gastrointestinal Symptom Rating Scale in patients with gastroesophageal reflux disease, *Qual. Life Res.*, 1998, **7**, 75–83.
- M. Srinivas, V. Srinivasan, M. Jain, C. S. R. Shanthi, V. Mohan and V. Jayanthi, A cross-sectional study of stool form (using Bristol stool chart) in an urban South Indian population, *JGH Open*, 2019, **3**, 464–467.
- S. Andrews, FastQC: A quality control tool for high throughput sequence data, <http://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.
- M. P. Cox, D. A. Peterson and P. J. Biggs, SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data, *BMC Bioinf.*, 2010, **11**, 485.
- J. G. Caporaso, J. Kuczynski, J. Stombaugh, K. Bittinger, F. D. Bushman, E. K. Costello, N. Fierer, A. G. Peña, J. K. Goodrich, J. I. Gordon, G. A. Huttley, S. T. Kelley, D. Knights, J. E. Koenig, R. E. Ley, C. A. Lozupone, D. McDonald, B. D. Muegge, M. Pirrung, J. Reeder, J. R. Sevinsky, P. J. Turnbaugh, W. A. Walters, Y. T. Widmann, J. Zaneveld and R. Knight, QIIME allows analysis of high-throughput community sequencing data, *Nat. Methods*, 2010, **7**, 335–336.
- B. J. Callahan, P. J. McMurdie, M. J. Rosen, A. W. Han and A. J. Johnson, Holmes S P. DADA2: High-resolution sample inference from Illumina amplicon data, *Nat. Methods*, 2016, **13**, 581–583.
- P. Yilmaz, L. W. Parfrey, P. Yarza, J. Gerken, E. Pruesse, C. Quast, T. Schweer, J. Peplies, W. Ludwig and



- F. O. Glöckner, The SILVA and “All-species Living Tree Project (LTP)” taxonomic frameworks, *Nucleic Acids Res.*, 2014, **42**, 643–648.
- 27 M. J. Anderson, Permutational Multivariate Analysis of Variance (PERMANOVA), *Wiley StatsRef: Statistics Reference Online*, 2017, vol. 2017, pp. 1–15.
- 28 S. Mandal, W. Van Treuren, R. A. White, M. Eggesbø, R. Knight and S. D. Peddada, Analysis of composition of microbiomes: a novel method for studying microbial composition, *Microb. Ecol. Health Dis.*, 2015, **26**, 27663.
- 29 D. Leffler, D. Schuppan, K. Pallav, R. Najarian, J. D. Goldsmith, J. Hansen, T. Kabbani, M. Dennis and C. P. Kelly, Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease, *Gut*, 2013, **62**, 996–1004.
- 30 C. Catassi, E. Fabiani, G. Iacono, C. D’Agate, R. Francavilla, F. Biagi, U. Volta, S. Accomando, A. Picarelli, I. De Vitis, G. Pianelli, R. Gesuita, F. Carle, A. Mandolesi, I. Bearzi and A. Fasano, A prospective, double-blind, placebo-controlled trial to establish a safe gluten threshold for patients with celiac disease, *Am. J. Clin. Nutr.*, 2007, **85**, 160–166.
- 31 A. Rostom, J. A. Murray and M. F. Kagnoff, American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease, *Gastroenterology*, 2006, **131**, 1981–2002.
- 32 M. N. Marsh, Crowe P T. Morphology of the mucosal lesion in gluten sensitivity, *Baillieres Clin. Gastroenterol.*, 1995, **9**, 273–293.
- 33 K. C. Niranjan, A. Tayaar, G. S. Kumar, R. Krishnapillai, K. Hallikeri and S. Hunasgi, Immunohistochemical expression of cyclin B1 in epithelial hyperplasia, dysplasia and oral squamous cell carcinomas - a comparative study, *J. Clin. Diagn. Res.*, 2016, **10**, 85–90.
- 34 J. König, J. Wells, P. D. Cani, C. L. García-Ródenas, T. MacDonald, A. Mercenier, J. Whyte, F. Troost and R. J. Brummer, Human intestinal barrier function in health and disease, *Clin. Transl. Gastroenterol.*, 2016, **7**, e196.
- 35 D. Cardoso-Silva, D. Delbue, A. Itzlinger, R. Moerkens, S. Withoff, F. Branchi and M. Schumann, Intestinal barrier function in gluten-related disorders, *Nutrients*, 2019, **11**, 2325.
- 36 J. A. Silvester, S. Kurada, A. Szwajcer, C. P. Kelly, D. A. Leffler and D. R. Duerksen, Tests for serum transglutaminase and endomysial antibodies do not detect most patients with celiac disease and persistent villous atrophy on gluten-free diets: a metaanalysis, *Gastroenterology*, 2017, **153**, 689–701.
- 37 B. L. Kelsall and M. Rescigno, Mucosal dendritic cells in immunity and inflammation, *Nat. Immunol.*, 2004, **5**, 1091–1095.
- 38 A. Fasano, T. Not, W. Wang, S. Uzzau, I. Berti, A. Tommasini and S. E. Goldblum, Zonulin, a newly discovered modulator of intestinal permeability, and its expression in coeliac disease, *Lancet*, 2000, **355**, 1518–1519.
- 39 J. F. Ludvigsson, C. Ciacci, P. H. Green, K. Kaukinen, I. R. Korponay-Szabo, K. Kurppa, J. A. Murray, K. E. A. Lundin, M. J. Maki, A. Popp, N. R. Reilly, A. Rodriguez-Herrera, D. S. Sanders, D. Schuppan, S. Sleet, J. Taavela, K. Voorhees, M. M. Walker and D. A. Leffler, Outcome measures in coeliac disease trials: the Tampere recommendations, *Gut*, 2018, **67**, 1410–1424.
- 40 A. M. Chander, H. Yadav, S. Jain, K. Bhadada and D. K. Dhawan, Cross-talk between gluten, intestinal microbiota and intestinal mucosa in celiac disease: recent advances and basis of autoimmunity, *Front. Microbiol.*, 2018, **9**, 2597.
- 41 S. Reddel, F. Del Chierico, A. Quagliariello, S. Giancristoforo, P. Vernocchi, A. Russo, A. Fiocchi, P. Rossi, L. Putignani and M. El Hachem, Gut microbiota profile in children affected by atopic dermatitis and evaluation of intestinal persistence of a probiotic mixture, *Sci. Rep.*, 2019, **9**, 4996.
- 42 K. H. Allin, V. Tremaroli, R. Caesar, B. A. H. Jensen, M. T. F. Damgaard, M. I. Bahl, T. R. Licht, T. H. Hansen, T. Nielsen, T. M. Dantoft, A. Linneberg, T. Jørgensen, H. Vestergaard, K. Kristiansen, P. W. Franks, IMI-DIRECT consortium, T. Hansen, F. Bäckhed and O. Pedersen, Aberrant intestinal microbiota in individuals with prediabetes, *Diabetologia*, 2018, **61**, 810–820.
- 43 J. L. Round and S. K. Mazmanian, The gut microbiota shapes intestinal immune responses during health and disease, *Nat. Rev. Immunol.*, 2009, **9**, 313–323.
- 44 O. O. Coker, Z. Dai, Y. Nie, G. Zhao, L. Cao, G. Nakatsu, W. K. Wu, S. H. Wong, Z. Chen, J. J. Y. Sung and J. Yu, Mucosal microbiome dysbiosis in gastric carcinogenesis, *Gut*, 2018, **67**, 1024–1032.
- 45 A. Caminero, H. J. Galipeau, J. L. McCarville, C. W. Johnston, S. P. Bernier, A. K. Russell, J. Jury, A. R. Herran, J. Casqueiro, J. A. Tye-Din, M. G. Surette, N. A. Magarvey, D. Schuppan and E. F. Verdu, Duodenal bacteria from patients with celiac disease and healthy subjects distinctly affect gluten breakdown and immunogenicity, *Gastroenterology*, 2016, **151**, 670–683.
- 46 P. M. Smith, M. R. Howitt, N. Panikov, M. Michaud, C. A. Gallini, M. Bohlooly-Y, J. N. Glickman and W. S. Garrett, The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis, *Science*, 2013, **341**, 569–573.
- 47 G. Serena, S. Yan, S. Camhi, S. Patel, R. S. Lima, A. Sapone, M. M. Leonard, R. Mukherjee, B. J. Nath, K. M. Lammers and A. Fasano, Proinflammatory cytokine interferon-gamma and microbiome-derived metabolites dictate epigenetic switch between forkhead box protein 3 isoforms in coeliac disease, *Clin. Exp. Immunol.*, 2017, **187**, 490–506.
- 48 L. Li, S. M. Batt, M. Wannemuehler, A. Dispirito and D. C. Beitz, Effect of feeding of a cholesterol-reducing bacterium, *Eubacterium coprostanoligenes*, to germ-free mice, *Lab. Anim. Sci.*, 1998, **48**, 253–255.
- 49 R. A. Luna, N. Oezguen, M. Balderas, A. Venkatachalam, J. K. Runge, J. Versalovic, J. Veenstra-VanderWeele,



- G. M. Anderson, T. Savidge and K. C. Williams, Distinct microbiome-neuroimmune signatures correlate with functional abdominal pain in children with autism spectrum disorder, *Cell. Mol. Gastroenterol. Hepatol.*, 2016, **3**, 218–230.
- 50 H. Qi, Y. Li, H. Yun, T. Zhang, Y. Huang, J. Zhou, H. Yan, J. Wei, Y. Liu, Z. Zhang, Y. Gao, Y. Che, X. Su, D. Zhu, Y. Zhang, J. Zhong and R. Yang, Lactobacillus maintains healthy gut mucosa by producing L-Ornithine, *Commun. Biol.*, 2019, **2**, 171.
- 51 Y. Furusawa, Y. Obata, S. Fukuda, T. A. Endo, G. Nakato, D. Takahashi, Y. Nakanishi, C. Uetake, K. Kato, T. Kato, M. Takahashi, N. N. Fukuda, S. Murakami, E. Miyauchi, S. Hino, K. Atarashi, S. Onawa, Y. Fujimura, T. Lockett, J. M. Clarke, D. L. Topping, M. Tomita, S. Hori, O. Ohara, T. Morita, H. Koseki, J. Kikuchi, K. Honda, K. Hase and H. Ohno, Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells, *Nature*, 2013, **504**, 446–450.
- 52 J. A. Rosero, J. Killer, H. Sechovcová, J. Mrázek, O. Benada, K. Fliegerová, J. Havlík and J. Kopečný, Reclassification of *Eubacterium rectale* (Hauduroy, *et al.* 1937) Prévot 1938 in a new genus *Agathobacter* gen. nov. as *Agathobacter rectalis* comb. nov., and description of *Agathobacter ruminis* sp. nov., isolated from the rumen contents of sheep and cows, *Int. J. Syst. Evol. Microbiol.*, 2016, **66**, 768–773.
- 53 T. P. Bui, J. Ritari, S. Boeren, P. de Waard, C. M. Plugge and W. M. de Vos, Production of butyrate from lysine and the Amadori product fructoselysine by a human gut commensal, *Nat. Commun.*, 2015, **6**, 10062.
- 54 I. Amir, P. Bouvet, C. Legeay, U. Gophna and A. Weinberger, *Eisenbergiella tayi* gen. nov., sp. nov., isolated from human blood, *Int. J. Syst. Evol. Microbiol.*, 2014, **64**, 907–914.
- 55 D. A. Elhag, M. Kumar and S. Al-Khodor, Exploring the triple interaction between the host Genome, the epigenome, and the gut microbiome in type 1 diabetes, *Int. J. Mol. Sci.*, 2021, **22**, 125.

